The University of California, San Francisco, and colleagues have conducted a study revealing that self-reported age at onset of hidradenitis suppurativa has a bimodal distribution, with peak common onset occurring in the late teens and peak late onset occurring in the mid-40s according to this retrospective study.

It is hoped that the findings will support more accurate and timely diagnosis of what is a very troubling condition reported Healio by author Julia Lowndes. The team published their findings in JAMA

The Study

The research team collected and analyzed data from 1,203 patients with a dermatologist -confirmed hidradenitis suppurativa (HS). The data included age at visit, self-reported age at onset, race, sex, self-identified ethnicity, and disease severity.

In this study, the UCSF-led team compared age at the onset across race, sex and disease severity using Wilcoxon tests, and Cullen-Fry plots for identification of age at onset as a log-normal distribution.

The Findings

The team found that sex was significantly associated with onset age—so they used a mixture of regression with sex as a covariate to identify subpopulations. As mentioned previously, self-reported age at onset of hidradenitis suppurativa has a bimodal distribution, with peak common onset occurring in the late teens and peak late onset occurring in the mid-40s.

Median age at onset was earlier for females than males (19 vs. 23 years; P.001). Additionally, the age at common onset for females was materially earlier than for males (16.8 years vs. 19.7 years; P.001).

Hispanics report younger than Blacks & Whites

Hispanic patients had earlier onset ages (18.5 years) than blacks (20 years; P=.03) and whites (20 years; P=.02).

Lead Investigator and Comments

Dr. Haley B. Naik led the study and reported: “These findings may help facilitate accurate and timely diagnosis of HS in a previously unrecognized HS subpopulation.”

Study Limitations

The research leads acknowledged that recall bias of self-reported age and variable disease duration could be studying limitations.

Lead Research/Investigator

Dr. Haley B. Naik, Dermatologist, UCSF

It was disclosed that Dr. Naik has performed consulting work for 23andMe as well as served as a co-investigator on a grant from AbbVie. It should be noted that AbbVie is very active in marketing and distributing Humira to HS patients via physician and provider system channels.

Source: Healio

Pin It on Pinterest